Stefano D. Pizzi , Alberto Granzotto, Manuela Bomba, Valerio Frazzini, Marco Onofrj and Stefano L. Sensi* Pages 790 - 804 ( 15 )
Brain aging and aging-related neurodegenerative disorders are posing a significant challenge for health systems worldwide. To date, most of the therapeutic efforts aimed at counteracting dementiarelated behavioral and cognitive impairment have been focused on addressing putative determinants of the disease, such as β-amyloid or tau. In contrast, relatively little attention has been paid to pharmacological interventions aimed at restoring or promoting the synaptic plasticity of the aging brain. The review will explore and discuss the most recent molecular, structural/functional, and behavioral evidence that supports the use of non-pharmacological approaches as well as cognitive-enhancing drugs to counteract brain aging and early-stage dementia.
Aging, β-amyloid, cognitive-enhancing drugs, dementia, fMRI, hyper-connectivity, neuronal reserve, tau, excitotoxicity, glutamate, cognitive stimulation, exercise.
Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology, CAST, University G. d'Annunzio of Chieti-Pescara, Pescara, Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology, CAST, University G. d'Annunzio of Chieti-Pescara, Pescara, Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology, CAST, University G. d'Annunzio of Chieti-Pescara, Pescara, AP-HP, Epilepsy Unit, Pitie-Salpetriere Hospital and Brain and Spine Institute (INSERM UMRS1127, CNRS UMR7225, Sorbonne Universite), Pitie-Salpetriere Hospital, Paris, Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology, CAST, University G. d'Annunzio of Chieti-Pescara, Pescara, Behavioral Neurology and Molecular Neurology Units, Center for Advanced Studies and Technology, CAST, University G. d'Annunzio of Chieti-Pescara, Pescara